363 related articles for article (PubMed ID: 25650317)
1. Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317
[TBL] [Abstract][Full Text] [Related]
2. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
[No Abstract] [Full Text] [Related]
7. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
8. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Caino MC; Altieri DC
Clin Cancer Res; 2016 Feb; 22(3):540-5. PubMed ID: 26660517
[TBL] [Abstract][Full Text] [Related]
10. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Gjerde CH; Enger PØ; Goplen D
BMC Cancer; 2016 Aug; 16():657. PubMed ID: 27542970
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
Thiagarajan PS; Wu X; Zhang W; Shi I; Bagai R; Leahy P; Feng Y; Veigl M; Lindner D; Danielpour D; Yin L; Rosell R; Bivona TG; Zhang Z; Ma PC
Oncotarget; 2016 Dec; 7(50):82013-82027. PubMed ID: 27852038
[TBL] [Abstract][Full Text] [Related]
12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
13. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
15. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
17. ω3-polyunsaturated fatty acids induce cell death through apoptosis and autophagy in glioblastoma cells: In vitro and in vivo.
Kim S; Jing K; Shin S; Jeong S; Han SH; Oh H; Yoo YS; Han J; Jeon YJ; Heo JY; Kweon GR; Park SK; Park JI; Wu T; Lim K
Oncol Rep; 2018 Jan; 39(1):239-246. PubMed ID: 29192322
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments.
Maiti P; Plemmons A; Dunbar GL
PLoS One; 2019; 14(12):e0225660. PubMed ID: 31841506
[TBL] [Abstract][Full Text] [Related]
19. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
20. A Novel Platinum-Maurocalcine Conjugate Induces Apoptosis of Human Glioblastoma Cells by Acting through the ROS-ERK/AKT-p53 Pathway.
Aroui S; Dardevet L; Ben Ajmia W; de Boisvilliers M; Perrin F; Laajimi A; Boumendjel A; Kenani A; Muller JM; De Waard M
Mol Pharm; 2015 Dec; 12(12):4336-48. PubMed ID: 26465677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]